|
1
|
Adachi M, Maeda K, Takekawa M, Hinoda Y,
Imai K, Sugiyama S and Yachi A: High expression of CD56 (N-CAM) in
a patient with cutaneous CD14 positive lymphoma. Am J Hematol.
47:278–282. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO classification of
tumours of haematopoietic and lymphoid tissues. (4th edition).
(Lyon, France). IARC Press. 191–194. 2008.
|
|
3
|
Bueno C, Almeida J, Lucio P, Marco J,
Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F,
Suarez-Vilela D, et al: Incidence and characteristics of CD4(+)/HLA
DRhi dendritic cell malignancies. Haematologica. 89:58–69.
2004.PubMed/NCBI
|
|
4
|
Julia F, Dalle S, Duru G, Balme B, Vergier
B, Ortonne N, Vignon-Pennamen MD, Costes-Martineau V, Lamant L,
Dalac S, et al: Blastic plasmacytoid dendritic cell neoplasms:
Clinico-immunohistochemical correlations in a series of 91
patients. Am J Surg Pathol. 38:673–680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chaperot L, Bendriss N, Manches O, Gressin
R, Maynadie M, Trimoreau F, Orfeuvre H, Corront B, Feuillard J,
Sotto JJ, et al: Identification of a leukemic counterpart of the
plasmacytoid dendritic cells. Blood. 97:3210–3217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Petrella T, Comeau MR, Maynadié M,
Couillault G, De Muret A, Maliszewski CR, Dalac S, Durlach A and
Galibert L: ‘Agranular CD4+ CD56+ hematodermicneoplasm’ (blastic
NK-cell lymphoma) originates from a population of CD56 +precursor
cells related to plasmacytoid monocytes. Am J Surg Pathol.
26:852–862. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Facchetti F, Pileri SA, Agostinelli C,
Martelli MP, Paulli M, Venditti A, Martelli MF and Falini B:
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid
dendritic cell neoplasm. Haematologica. 94:285–288. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Garnache-Ottou F, Feuillard J and Saas P:
Plasmacytoid dendritic cell leukaemia/lymphoma: Towards a well
defined entity? Br J Haematol. 136:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pagano L, Valentini CG, Pulsoni A, Fisogni
S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C,
et al: Blastic plasmacytoid dendritic cell neoplasm with leukemic
presentation: An Italian multicenter study. Haematologica.
98:239–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Julia F, Petrella T, Beylot-Barry M, Bagot
M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M,
et al: Blastic plasmacytoid dendritic cell neoplasm: Clinical
features in 90 patients. Br J Dermatol. 169:579–586. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dalle S, Beylot-Barry M, Bagot M, Lipsker
D, Machet L, Joly P, Dompmartin A, d'Incan M, Maubec E, Grange F,
et al: Blastic plasmacytoid dendritic cell neoplasm: Is
transplantation the treatment of choice? Br J Dermatol. 162:74–79.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petrella T, Bagot M, Willemze R,
Beylot-Barry M, Vergier B, Delaunay M, Meijer CJ, Courville P, Joly
P, Grange F, et al: Blastic NK-cell lymphomas (agranularCD4+CD56+
hematodermic neoplasms): A review. Am JClin Pathol. 123:662–675.
2005. View Article : Google Scholar
|
|
13
|
Cota C, Vale E, Viana I, Requena L,
Ferrara G, Anemona L, Metze D, Fink-Puches R, Wiesner T and Cerroni
L: Cutaneous manifestations of blastic plasmacytoid dendritic cell
neoplasm-morphologic and phenotypic variabilityin a series of 33
patients. Am J Surg Pathol. 34:75–87. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jegalian AG, Buxbaum NP, Facchetti F,
Raffeld M, Pittaluga S, Wayne AS and Jaffe ES: Blastic plasmacytoid
dendritic cell neoplasm in children: Diagnostic features and
clinical implications. Haematologica. 95:1873–1879. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tokuda K, Eguchi-Ishimae M, Yagi C, Kawabe
M, Moritani K, Niiya T, Tauchi H, Ishii E and Eguchi M: CLTC-ALK
fusion as a primary event in congenital blastic plasmacytoid
dendritic cell neoplasm. Genes Chromosomes Cancer. 53:78–89. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rauh MJ, Rahman F, Good D, Silverman J,
Brennan MK, Dimov N, Liesveld J, Ryan DH, Burack WR and Bennett JM:
Blastic plasmacytoid dendritic cell neoplasm with leukemic
presentation, lacking cutaneous involvement: Case series and
literature review. Leuk Res. 36:81–86. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki R, Nakamura S, Suzumiya J, Ichimura
K, Ichikawa M, Ogata K, Kura Y, Aikawa K, Teshima H, Sako M, et al:
Blastic natural killer cell lymphoma/leukemia (CD56-positive
blastic tumor): Prognostication and categorization according to
anatomic sites of involvement. Cancer. 104:1022–1031. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Starck M, Zewen S, Eigler A and Wendtner
CM: Meningeal spread of blastic plasmacytoid dendritic cell
neoplasm. Eur J Haematol. 93:175–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maio P, Fernandes C, Afonso A, Sachse F,
Cabeçadas J and Cardoso J: Case for diagnosis. An Bras Dermatol.
88:131–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tamura H, Ogata K, Mori S, An E, Tajika K,
Sugisaki Y and Dan K: Lymphoblastic lymphoma of natural killer cell
origin, presenting as pancreatic tumor. Histopathology. 32:508–511.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim Y, Kang MS, Kim CW, Sung R and Ko YH:
CD4+ CD56 + lineage negative hematopoietic neoplasm: So called
blastic NK cell lymphoma. J Korean Med Sci. 20:319–324. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi Y and Wang E: Blastic plasmacytoid
dendritic cell neoplasm: A clinicopathologic review. Arch Pathol
Lab Med. 138:564–569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dzionek A, Fuchs A, Schmidt P, Cremer S,
Zysk M, Miltenyi S, Buck DW and Schmitz J: BDCA-2, BDCA-3, and
BDCA-4: Three markers for distinct subsets of dendritic cells in
human peripheral blood. J Immunol. 165:6037–6046. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jaye DL, Geigerman CM, Herling M, Eastburn
K, Waller EK and Jones D: Expression of the plasmacytoid dendritic
cell marker BDCA-2 supports a spectrum of maturation among
CD4+CD56+ hematodermic neoplasms. Mod Pathol. 19:1555–1562. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pilichowska ME, Fleming MD, Pinkus JL and
Pinkus GS: CD4+/CD56+ hematodermic neoplasm (‘blastic natural
killer cell lymphoma’): Neoplastic cells express the immature
dendritic cell marker BDCA-2 and produce interferon. Am J Clin
Pathol. 128:445–453. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herling M, Teitell MA, Shen RR, Medeiros
LJ and Jones D: TCL1 expression in plasmacytoid dendritic cells
(DC2s) and the related CD4+CD56+ blastic tumors of skin. Blood.
101:5007–5009. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Petrella T, Meijer CJ, Dalac S, Willemze
R, Maynadié M, Machet L, Casasnovas O, Vergier B and Teitell MA:
TCL1 and CLA expression in agranular CD4/CD56 hematodermic
neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin
Pathol. 122:307–313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leenman EE and Krivolapov IuA:
Morphological and immunohistochemical characteristics of blastic
NK-cell lymphoma. Arkh Patol. 67:35–37. 2005.(In Russian).
PubMed/NCBI
|
|
29
|
Leroux D, Mugneret F, Callanan M,
Radford-Weiss I, Dastugue N, Feuillard J, Le Mée F, Plessis G,
Talmant P, Gachard N, et al: CD4(+), CD56(+) DC2 acute leukemia is
characterized by recurrent clonal chromosomal changes affecting 6
major targets: A study of 21 cases by the Groupe Français de
Cytogénétique Hématologique. Blood. 99:4154–4159. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alayed K, Patel KP, Konoplev S, Singh RR,
Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN,
et al: TET2 mutations, myelodysplastic features, and a distinct
immunoprofile characterize blastic plasmacytoid dendritic cell
neoplasm in the bone marrow. Am J Hematol. 88:1055–1061. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wiesner T, Obenauf AC, Cota C, Fried I,
Speicher MR and Cerroni L: Alterations of the cell-cycle inhibitors
p27(KIP1) and p16(INK4a)are frequent in blastic plasmacytoid
dendritic cell neoplasms. J Invest Dermatol. 130:1152–1157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dijkman R, van Doorn R, Szuhai K, Willemze
R, Vermeer MH and Tensen CP: Gene-expression profiling and
array-based CGH classify CD4+CD56+ hematodermic neoplasm and
cutaneous myelomonocytic leukemia as distinct disease entities.
Blood. 109:1720–1727. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Menezes J, Acquadro F, Wiseman M,
Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV,
Montes-Moreno S, Hernández-Rivas JM, et al: Exome sequencing
reveals novel and recurrent mutations with clinical impact in
blastic plasmacytoid dendritic cell neoplasm. Leukemia. 28:823–829.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lopez V, Martí N, Ferrández A, Martin JM
and Jordá E: An atypical presentation of a blastic plasmacytoid
dendritic cell tumors. J Cutan Pathol. 37:e50–e52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fontaine J, Thomas L, Balme B,
Ronger-Savle S, Traullé C, Petrella T and Dalle S:
HaematodermicCD4+CD56+ neoplasm: Complete remission after
methotrexate-asparaginase treatment. Clin Exp Dermatol. 34:e43–e45.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gruson B, Vaida I, Merlusca L, Charbonnier
A, Parcelier A, Damaj G, Royer B and Marolleau JP: L-asparaginase
with methotrexate and dexamethasone is an effective treatment
combination in blastic plasmacytoid dendritic cell neoplasm. Br J
Haematol. 163:543–545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hatano Y, Ogata M, Ohishi M, Anan T, Senba
K, Yasumatsu T, Katagiri K, Kashima K, Yokoyama S, Kadota JI, et
al: Maintenance of long-term remission using oral administration of
low-dose etoposide in a patient demonstrating a relapse of blastic
natural killer-cell lymphoma. Clin Exp Dermatol. 32:96–97.
2007.PubMed/NCBI
|
|
38
|
Roos-Weil D, Dietrich S, Boumendil A,
Polge E, Bron D, Carreras E, Atienza Iriondo A, Arcese W, Beelen
DW, Cornelissen JJ, et al: Stem cell transplantation can provide
durable disease control in blastic plasmacytoid dendritic cell
neoplasm: A retrospective study from the European Group for Blood
and Marrow Transplantation. Blood. 121:440–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Suzuki R, Suzumiya J, Nakamura S, Kagami
Y, Kameoka JI, Sakai C, Mukai H, Takenaka K, Yoshino T, Tsuzuki T,
et al: Hematopoietic stem cell transplantation for natural
killer-cell lineage neoplasms. Bone Marrow Transplant. 37:425–431.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frankel AE, Woo JH, Ahn C, Pemmaraju N,
Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA,
Konopleva M, et al: Activity of SL-401, a targetedtherapy directed
to interleukin-3 receptor, in blastic plasmacytoid dendritic cell
neoplasm patients. Blood. 124:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sapienza MR, Fuligni F, Agostinelli C,
Tripodo C, Righi S, Laginestra MA, Pileri A Jr, Mancini M, Rossi M,
Ricci F, et al: Molecular profiling of blastic plasmacytoid
dendritic cell neoplasm reveals a unique pattern and suggests
selective sensitivity to NF-κB pathway inhibition. Leukemia.
28:1606–1616. 2014. View Article : Google Scholar : PubMed/NCBI
|
